You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(01177.HK)中期純利升583.6%至84.80億元 新產品銷售收入佔比升至43.9%
格隆匯 08-31 16:53

格隆匯8月31日丨中國生物製藥(01177.HK)公佈截至2021年6月30日止6個月的中期業績,集團錄得收入約人民幣143.54億元,同比增長約13.5%;歸屬於母公司持有者應占盈利約人民幣84.80億元,同比增長約583.6%;扣除應占聯營公司及合營公司盈利╱(虧損)及相關税項後,調整後歸屬於母公司持有者應占盈利約人民幣15.75億元,同比增長約22.9%;每股基本盈利45.15分,宣派第二季度股息每股2港仙,連同已派發第一季度股息每股2港仙,首兩季度合共派發股息每股4港仙。

公吿顯示,新產品銷售收入佔集團總收入比例從去年約34.8%上升至期內約43.9%。於期末,現金及銀行結餘約人民幣80.28億元。

集團繼續專注肝病、抗腫瘤、呼吸系統和心腦血管等治療領域的新產品研發。於第二季度內,集團獲得註冊批件10件、臨牀批件17件及一致性評價獲批22個、申報臨牀15件及申報生產8個。已累計有臨牀批件、正在進行臨牀試驗和申報生產的在研產品共393件,其中肝病用藥39件、抗腫瘤用藥185件、呼吸系統用藥25件、內分泌用藥17件、心腦血管用藥16件及其它類用藥111件。

一直以來,集團十分重視研發,以結合自主創新、聯合開發及創仿開發的研發理念,不斷提升研發水平和速度,並視其為可持續發展的基礎,加大研發的資金投入。截至2021年6月30日止6個月,研發總開支約人民幣18.81億元,佔集團收入約13.1%,已計入損益表及資本化於財務狀況表中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account